Related Experiment Video

Updated: Jun 14, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

17.9K

MitoAMPK inhibits the Warburg effect by MZF1-SIRT6 with glycosis related genes in NSCLC

Shangyu Li1, Jinyao He1,2, Lijie Zhang1

  • 1Institute of Hematological Research, Shaanxi Provincial People's Hospital, Xi'an, China.

Journal of Cellular and Molecular Medicine
|September 3, 2024
PubMed

Insights

Mitochondrial AMPK inhibits the Warburg effect in non-small-cell lung cancer by regulating the MZF1-SIRT6 complex, impacting glycolysis-related genes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Metabolism

Background:

  • The Warburg effect is a hallmark of cancer, promoting tumor growth.
  • Mitochondrial AMPK (mitoAMPK) is known to inhibit the Warburg effect.
  • The precise mechanisms of mitoAMPK in non-small-cell lung cancer (NSCLC) require further elucidation.

Purpose of the Study:

  • To investigate the role of SIRT6 and MZF1 in the mechanism by which mitoAMPK inhibits the Warburg effect in NSCLC.
  • To clarify the molecular interactions and regulatory pathways involved.

Main Methods:

  • Western blotting and quantitative polymerase chain reaction (qPCR) to assess protein and gene expression.
  • Cell Counting Kit-8 (CCK-8) assay for cell proliferation.
  • Immunohistochemistry assays for tissue analysis.
  • Chromatin immunoprecipitation (ChIP)-qPCR to confirm protein-DNA interactions.

Main Results:

  • SIRT6 expression was significantly lower in NSCLC tissues and cell lines compared to normal controls.
  • SIRT6 inhibited the Warburg effect by downregulating glycolysis-related genes: SLC2A2, SLC2A4, and PKM2.
  • A direct interaction between SIRT6 and MZF1 was confirmed.

Conclusions:

  • MitoAMPK inhibits the Warburg effect in NSCLC.
  • This inhibition is mediated through the regulation of the MZF1-SIRT6 complex.
  • SIRT6 acts as a key regulator in this pathway, impacting key glycolytic genes.
Keywords:
MZF1SIRT6Warburg effectglycolysismitochondrial AMPKnon‐small‐cell lung cancer

More Related Videos

Assessment of Mitochondrial Health in Cancer-Associated Fibroblasts Isolated from 3D Multicellular Lung Tumor Spheroids10:26

Assessment of Mitochondrial Health in Cancer-Associated Fibroblasts Isolated from 3D Multicellular Lung Tumor Spheroids

Published on: October 21, 2022

1.9K
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

19.6K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
12.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K